ANI Pharmaceuticals, Inc. (ANIP)
NASDAQ: ANIP · Real-Time Price · USD
53.35
-0.91 (-1.68%)
Dec 20, 2024, 4:00 PM EST - Market closed

Company Description

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.

It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals.

ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals logo
Country United States
Founded 2001
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 642
CEO Nikhil Lalwani

Contact Details

Address:
210 Main Street West
Baudette, Minnesota 56623
United States
Phone 218 634 3500
Website anipharmaceuticals.com

Stock Details

Ticker Symbol ANIP
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001023024
CUSIP Number 00182C103
ISIN Number US00182C1036
Employer ID 58-2301143
SIC Code 2834

Key Executives

Name Position
Nikhil Lalwani President, Chief Executive Officer and Director
Stephen P. Carey Senior Vice President of Finance and Chief Financial Officer
Chad Gassert Senior Vice President of Corporate Development and Strategy
Christopher K. Mutz Senior Vice President and Head of Rare Disease
Ori Gutwerg Senior Vice President of Generics
Muthusamy Shanmugam MS R.Ph. Head of Research & Development, Chief Operating Officer of Novitium Operations and Director
James G. Marken Senior Vice President of Operations
Elizabeth Powell J.D. Chief Compliance Officer and Head of Legal of Rare Disease
Meredith W. Cook J.D. Senior Vice President, General Counsel and Corporate Secretary
Krista L. Davis Senior Vice President and Chief Human Resources Officer

Latest SEC Filings

Date Type Title
Dec 17, 2024 144 Filing
Nov 26, 2024 144 Filing
Nov 20, 2024 8-K Current Report
Nov 13, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 8, 2024 10-Q Quarterly Report
Nov 8, 2024 8-K Current Report
Sep 20, 2024 8-K Current Report
Sep 16, 2024 8-K Current Report
Aug 13, 2024 8-K Current Report
Aug 8, 2024 8-K Current Report